| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a80cbaaeee718664126e579cf4e41c2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 |
| filingDate |
2021-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2c3d4b908392e2d4ccd2fc50880749a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7160ef09b22b0b3b5c92e30f02e2ecf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0399e38cc2a5f3b12b325aa657d3fcdc |
| publicationDate |
2022-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022115526-A1 |
| titleOfInvention |
Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist |
| abstract |
Disclosed herein is a method of treatment or prevention of public speaking anxiety (PSA), which may in some cases present as a symptom of social anxiety disorder (SAD), including the performance only (SAD-PO) subtype of SAD. The method of treatment includes administering an α7 nAChR agonist such as (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane to the individual at a therapeutically effective dose. |
| priorityDate |
2020-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |